Anzeige
Mehr »
Login
Donnerstag, 04.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Transformation! PepsiCo-Top-Manager übernimmt Ruder bei BevCanna
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H5NT ISIN: SE0008321202 Ticker-Symbol: 4Z7 
Stuttgart
04.03.21
12:42 Uhr
0,600 Euro
+0,026
+4,53 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IRRAS AB Chart 1 Jahr
5-Tage-Chart
IRRAS AB 5-Tage-Chart

Aktuelle News zur IRRAS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.02.IRRAS AB publishes Year End Report for the period January to December 2020172STOCKHOLM, Feb. 16, 2021 /PRNewswire/ -- Growth despite COVID-19 resurgence "During the course of the 4th quarter, challenges associated with the COVID-19 global pandemic increased...
► Artikel lesen
09.02.IRRAS: Q4 Report 2020 - invitation to conference call and audiocast-
IRRAS Aktie jetzt für 0€ handeln
12.01.IRRAS Announces Collaboration with Karolinska University Hospital211- Collaboration agreement with Neurosurgery Department of Karolinska University Hospital will further enhance the usage of the company's transformative IRRAflow system to benefit neurocritical...
► Artikel lesen
17.12.20IRRAS Announces Expansion of IRRAflow Launch to Southeastern Europe227- Finalization of agreement with additional distribution partner allows access into another key European market - Medical Innovation Solutions is a well-established partner with deep...
► Artikel lesen
10.12.20IRRAS Announces Expansion of IRRAflow Launch to Latin America242- Finalization of agreement with distribution partner in Argentina allows access into initial Latin American markets - Anade SA is a well-established partner with deep existing relationships...
► Artikel lesen
26.11.20IRRAS Announces Expansion of IRRAflow Launch to The Netherlands274- Finalization of agreement with Dutch distribution partner allows access into another key European market - KM Innovations is a well-established partner with deep existing relationships...
► Artikel lesen
17.11.20IRRAS Awarded Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products227- Premier is one of the leading healthcare improvement companies in the United States, uniting an alliance of approximately 4,100 US hospitals and 200,000 providers. - Hummingbird family...
► Artikel lesen
10.11.20IRRAS AB reports Q3 results1
10.11.20IRRAS AB publishes Interim Report for the period January to September 2020157IRRAS' progress continues and sales increase STOCKHOLM, Nov. 10, 2020 /PRNewswire/ -- "During the third quarter IRRAS made decisive progress in a number of areas. Sales growth was seen...
► Artikel lesen
04.11.20IRRAS: Q3 Report 2020 - invitation to conference call and audiocast243STOCKHOLM, Nov. 4, 2020 /PRNewswire/ -- On Tuesday November 10, at 16.00 CET, IRRAS will host a conference call and an online presentation of its Q3 2020 interim report (which will have been...
► Artikel lesen
22.10.20IRRAS Announces Key IRRAflow Commercial Milestones in Germany278STOCKHOLM, Oct. 22, 2020 /PRNewswire/ -- IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced...
► Artikel lesen
29.09.20IRRAS Announces Release of Clinical Data that Validates Safety and Effectiveness of IRRAflow System in Treating Chronic Subdural Hematomas301Length of hospitalization reduced by more than 50% versus US national average No complications or recurrence of bleeding seen during patient treatments at University of California Irvine STOCKHOLM...
► Artikel lesen
22.09.20IRRAS Enhances Global Sales Organization, Adds Key Talent to Drive Adoption of its IRRAflow and Hummingbird Product Lines1
25.08.20IRRAS Granted Sixth Patent for Hummingbird ICP Monitoring Product Line from United States Patent and Trademark Office (USPTO)286STOCKHOLM, Aug. 25, 2020 /PRNewswire/ -- IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced...
► Artikel lesen
20.08.20IRRAS: Q2 Report 2020 - invitation to conference call and audiocast214STOCKHOLM, Aug. 20, 2020 /PRNewswire/ -- On Thursday August 27, at 16.00 CET, IRRAS will host a conference call and an online presentation of its Q2 2020 interim report (which will have been...
► Artikel lesen
11.08.20IRRAS Announces First Global Patient Treatment with Newly Developed Hummingbird Solo ICP Monitoring System271Initial patient treatment confirms system's accuracy and ease of use US launch of Hummingbird Solo system expands the Hummingbird ICP Monitoring product family, allowing IRRAS to more completely...
► Artikel lesen
05.08.20IRRAS to Present Virtually at Upcoming Investor Conferences274STOCKHOLM, Aug. 5, 2020 /PRNewswire/ -- IRRAS, a global healthcare company with a comprehensive portfolio of innovative products for neurocritical care, today announced that company management...
► Artikel lesen
22.07.20IRRAS Announces Extension of CE Mark for IRRAflow System Until May 2024277- European Union regulatory approval in place for IRRAflow Control Unit, Tube Sets, and Single-use Catheters until May 2024 - Extension of CE Mark expiration date ensures commercial...
► Artikel lesen
11.06.20XFRA FRA:New Instruments available on XETRA - 11.06.2020-002383The following instruments on XETRA do have their first trading day 11.06.2020 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 11.06.2020 TrdMod InstCode Exch ISIN Name InstGrp InstType...
► Artikel lesen
20.05.20Nasdaq Nordic: Nasdaq Stockholm welcomes IRRAS to the Main Market751Stockholm, May 20, 2020 - Nasdaq (Nasdaq: NDAQ) announces that the trading in IRRAS AB's shares (short name: IRRAS) will commence today on the Nasdaq Stockholm main market. IRRAS belongs to the health...
► Artikel lesen
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1